Gastroesophageal reflux disease (GERD) is prevalent globally and represents one of the most common gastrointestinal diseases. The term GERD covers a spectrum of conditions, including non-erosive gastroesophageal reflux disease. (NERD) This condition is defined as at least weekly heartburn and regurgitation. Vonprazan is in a new class of acid-inhibitory agents called competitive potassium blockers. Recent studies have shown a rapid onset of action after the first dose providing relief.
Many factors contribute to the development of non-erosive reflux disease, including:
Non-erosive reflux disease produces the same symptoms as gastroesophageal reflux disease but without damaging the esophagus. Symptoms of Non-erosive reflux disease can include:
If you experience non-erosive reflux disease at night you might experience:
ICRMD Clinical Studies Participation
What we need:
The subject is ≥18 years of age at the time of informed consent signing
The subject identified their main symptom as heartburn, a burning sensation in the retrosternal area (behind the breastbone)
History of episodes of heartburn for 6 months or longer before screening
Heartburn reported on 4 or more days during any 7 consecutive days in the Screening Period as recorded in the electronic diary
What we cannot have:
The subject has irritable bowel syndrome (IBS)
The subject has endoscopic Barrett’s esophagus (>1 cm of columnar-lined esophagus) and/or definite dysplastic changes in the esophagus
The subject has a history of surgery or endoscopic treatment affecting gastroesophageal reflux, including fundoplication and dilation for esophageal stricture (except Schatzki’s ring), or a history of gastric or duodenal surgery (except endoscopic removal of benign polyps)
The subject has any other condition affecting the esophagus (Ask to view the full list of conditions)
Be sure to contact our Investigative Clinical Research studies center in Annapolis, Maryland, online at icrmd.com or call us at 410-224-4887.